The Annals of Pharmacotherapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes
CONCLUSION AND RELEVANCE: Older adults with nonvalvular AF are commonly prescribed lower-than-recommended doses of apixaban. However, no significant association was found between empiric off-label reduced dosing and stroke or bleeding outcomes.PMID:37712551 | DOI:10.1177/10600280231199137 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - September 15, 2023 Category: Drugs & Pharmacology Authors: Ashley M Campbell Elizabeth Pae Eunice Lee Timothy Jacisin Alina Price Jessica DeAngelo Source Type: research

Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist
CONCLUSION: Sparsentan reduces proteinuria in IgAN and FSGS, and has expedited approval by the FDA for IgAN in patients at risk of rapid disease progression, generally at urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. Interim results from PROTECT and results from DUET showed promise for improving proteinuria in IgAN and FSGS. Long-term renal function benefit and safety data are pending.PMID:37706310 | DOI:10.1177/10600280231198925 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - September 14, 2023 Category: Drugs & Pharmacology Authors: Ada W Chiu Nina Bredenkamp Source Type: research

Evaluation of Basal Plus Versus Sliding Scale Insulin Therapy on Glucose Variability in Critically Ill Patients Without Preexisting Diabetes
CONCLUSIONS AND RELEVANCE: The use of SSI compared with a BPI regimen may result in reduced glycemic variability in critically ill patients without preexisting diabetes. Future prospective studies, with a larger sample size, are warranted to confirm our exploratory findings and characterize clinically significant benefits.PMID:37700565 | DOI:10.1177/10600280231197255 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - September 13, 2023 Category: Drugs & Pharmacology Authors: Rachel E Webster Julie J Belfer Kyle J Schmidt Source Type: research

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib
CONCLUSION: Sotorasib and adagrasib demonstrated promising outcomes in targeting the constitutively active KRAS G12C oncogenic driver, underscoring the need for further research to optimize their therapeutic application in this high-risk population.PMID:37700573 | DOI:10.1177/10600280231197459 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - September 13, 2023 Category: Drugs & Pharmacology Authors: Natalie Mausey Zachery Halford Source Type: research

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients
CONCLUSION AND RELEVANCE: The median C0/D values were 90.38% higher in kidney transplant recipients with CYP3A5*3/*3 genotype than in those with CYP3A5*1/*1 or CYP3A5*1/*3 genotype when treated with both tacrolimus and voriconazole. A CYP3A5 genotype-dependent DDI was found between tacrolimus and voriconazole. Therefore, personalized therapy accounting for CYP3A5 genotype detection and therapeutic drug monitoring is necessary for kidney transplant patients when treating with tacrolimus and voriconazole.PMID:37702380 | DOI:10.1177/10600280231197399 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - September 13, 2023 Category: Drugs & Pharmacology Authors: Yundi Zhang Yue Du Shuyu Ren Yue Li Xiaoming Zhang Xiaohong Cao Fengxi Liu Huiying Zong Yan Li Source Type: research

Intranasal Theophylline: Potential Treatment for Long COVID Olfactory Dysfunction?
Ann Pharmacother. 2023 Sep 7:10600280231194960. doi: 10.1177/10600280231194960. Online ahead of print.NO ABSTRACTPMID:37675960 | DOI:10.1177/10600280231194960 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - September 7, 2023 Category: Drugs & Pharmacology Authors: Olga Hilas Tina Caliendo Source Type: research

Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review
CONCLUSIONS: Oteseconazole is an effective and safe treatment option for the management of RVVC though current research lacks comparison with established maintenance regimens. Additional research is needed to ascertain the placement of oteseconazole in the treatment of RVVC.PMID:37650387 | DOI:10.1177/10600280231195649 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 31, 2023 Category: Drugs & Pharmacology Authors: Cameron Lanier Tyler C Melton Source Type: research

Invasive SCC and Tirbanibulin: Experience in Patient With Epidermodysplasia Verruciformis
Ann Pharmacother. 2023 Aug 31:10600280231195899. doi: 10.1177/10600280231195899. Online ahead of print.NO ABSTRACTPMID:37650424 | DOI:10.1177/10600280231195899 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 31, 2023 Category: Drugs & Pharmacology Authors: Andrea Agostini Nicole Macagno Rebecca Senetta Pietro Quaglino Paolo Broganelli Source Type: research